Shanghai Yizhong Pharmaceutical Co., Ltd.

SHSE:688091 Stock Report

Market Cap: CN¥6.2b

Shanghai Yizhong Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Shanghai Yizhong Pharmaceutical has been growing earnings at an average annual rate of 78.3%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 76.2% per year. Shanghai Yizhong Pharmaceutical's return on equity is 11%, and it has net margins of 44.8%.

Key information

78.3%

Earnings growth rate

80.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate76.2%
Return on equity11.0%
Net Margin44.8%
Next Earnings Update30 Apr 2024

Recent past performance updates

Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Apr 15
Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Recent updates

Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Apr 15
Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely

Mar 29
Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely

Revenue & Expenses Breakdown
Beta

How Shanghai Yizhong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688091 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2336016215322
30 Sep 2334916914520
31 Mar 232941671189
31 Dec 222361431018
30 Sep 22170120735
30 Jun 227669297
31 Mar 2238322211
31 Dec 214-41813
30 Sep 210-271618
30 Jun 210-241319
31 Mar 210-221317
31 Dec 200-221218
31 Dec 190-315144179
31 Dec 180-13714

Quality Earnings: 688091 has a high level of non-cash earnings.

Growing Profit Margin: 688091's current net profit margins (44.8%) are lower than last year (60.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688091 has become profitable over the past 5 years, growing earnings by 78.3% per year.

Accelerating Growth: 688091's earnings growth over the past year (13.1%) is below its 5-year average (78.3% per year).

Earnings vs Industry: 688091 earnings growth over the past year (13.1%) exceeded the Pharmaceuticals industry 6.8%.


Return on Equity

High ROE: 688091's Return on Equity (11%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.